ScholarLens Back to search
1993•Drug and Therapeutics BulletinRequires access

▾ Filgrastim – human granulocyte-colony stimulating factor

Author information unavailable

Open publisher page 2 citations

Abstract

Filgrastim (recombinant human granulocyte-colony stimulating factor) (Neupogen – Amgen-Roche) was the first of several white cell ‘colony stimulating factors’ to be licensed for use in Britain. Filgrastim stimulates specifically the production of neutrophils from progenitor cells in the bone marrow, speeds their maturation and increases their number in the peripheral blood.1,2 Use of filgrastim is intended to reduce the duration and severity of myelosuppression that follows intensive cytotoxic chemotherapy. The manufacturer claims that filgrastim “supports full dose chemotherapy on time”, by moderating neutropenia and reducing the risk of infection that might interfere with the next cycle of treatment. When should filgrastim be given?

About this research paper

What this paper is about

Filgrastim (recombinant human granulocyte-colony stimulating factor) (Neupogen – Amgen-Roche) was the first of several white cell ‘colony stimulating factors’ to be licensed for use in Britain. Filgrastim stimulates specifically the production of neutrophils from progenitor cells in the bone marrow, speeds their maturation and increases their number in the peripheral blood.1,2 Use of filgrastim is intended to reduce the duration and severity of myelosuppression that follows intensive cytotoxic chemotherapy. The manufacturer claims that filgrastim “supports full dose chemotherapy on time”, by moderating neutropenia and reducing the risk of infection that might interfere with the next cycle of treatment. When should filgrastim be given?

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Filgrastim (recombinant human granulocyte-colony stimulating factor) (Neupogen – Amgen-Roche) was the first of several white cell ‘colony stimulating factors’ to be licensed for use in Britain. Filgrastim stimulates specifically the production of neutrophils from progenitor cells in the bone marrow, speeds their maturation and increases their number in the peripheral blood.1,2 Use of filgrastim is intended to reduce the duration and severity of myelosuppression that follows intensive cytotoxic chemotherapy. The manufacturer claims that filgrastim “supports full dose chemotherapy on time”, by moderating neutropenia and reducing the risk of infection that might interfere with the next cycle of treatment. When should filgrastim be given?

Key concepts: Filgrastim, Neutropenia, Granulocyte colony-stimulating factor, Medicine, Granulocyte, Bloodstream infection, Chemotherapy, Immunology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
▾ Filgrastim – human granulocyte-colony stimulating factor — Research Paper | ScholarLens